MEDIA ADVISORY, Aug. 31, 2006 (PRIMEZONE) --
What: Mark Mosteller - Chief Financial Officer of GTx, Inc. (GTXI) will preside over the closing bell to recognize Prostate Cancer Awareness Month. Where: NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio When: Friday, September 1st, 2006 at 4:00 p.m. EDT Contacts: McDavid Stilwell Manager, Corporate Communications 901-523-9700 x214 mstilwell@gtxinc.com NASDAQ MarketSite: Stephanie Lowenthal; 646.441.5220
Feed Information:
The closing bell is available from 3:50 p.m. to 4:05 p.m. on uplink IA-6 C-band/transponder 17. The downlink frequency is 4040 Vertical; Audio 6.2-6.8. The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Stephanie Lowenthal at (646) 441-5220.
Photos:
To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About GTx, Inc. (GTXI):
GTx, headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics for cancer and serious conditions related to men's health. GTx's lead drug discovery and development programs are focused on small molecules that selectively modulate the effects of estrogens and androgens, two essential classes of hormones. GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a pivotal Phase III clinical trial for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. GTx is developing ostarine, a selective androgen receptor modulator, or SARM, for muscle wasting and bone loss indications. Ostarine is currently being evaluated in a Phase II clinical trial in 120 elderly men and postmenopausal women. GTx expects to have data from the Phase II ostarine trial in the fourth quarter of 2006. GTx has licensed to Ortho Biotech Products, L.P., a subsidiary of Johnson & Johnson, another of its SARMs, andarine, under a joint collaboration and license agreement.